
1. j med chem. 2014 mar 13;57(5):1964-75. doi: 10.1021/jm401337x. epub 2013 nov 23.

imidazopyridazine hepatitis c virus polymerase inhibitors. structure-activity
relationship studies discovery novel, traceless prodrug mechanism.

leivers m(1), miller jf, chan sa, lauchli r, liehr s, mo w, ton t, turner em,
youngman m, falls jg, long s, mathis a, walker j.

author information: 
(1)glaxosmithkline research & development , 5 moore drive, research triangle
park, north carolina 27709, united states.

by reducing basicity core heterocycle series hcv ns5b
inhibitors, herg liability reduced. sar systematically
explored order increase solubility enable dose escalation while
retaining potency. exploration, facile decarboxylation noted
and exploited novel prodrug mechanism. synthesis and
characterization prodrugs utilization chronic toxicity
studies presented.

doi: 10.1021/jm401337x 
pmid: 24224729  [indexed medline]

